ORAGENICS

Oragenics, Inc. is a biotechnology company specializing in nasal drug delivery for neurological and rare diseases. The company's lead program, ONP-002, is an intranasal neurosteroid in development for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. Oragenics is also advancing ONP-001, which is a First-in-Class Enantiomeric-Neurosteroid being developed for the treatment of rare Leukodystrophies... By integrating cutting-edge therapeutics with advanced drug delivery technology, Oragenics aims to transform the treatment landscape for brain-related health conditions, addressing significant unmet medical needs.

Also known as: Oragenics, Inc.

Primary location: Sarasota United States